Anika Therapeutics ANIK Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $116.26M+3.1% | $112.82M+37.2% | $82.2M-11.7% | $93.14M-12.8% | $106.84M-11.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Anika Therapeutics's revenue?
- Anika Therapeutics (ANIK) generated $116.3M in revenue over the trailing twelve months, up 8.8% year over year.
- Is Anika Therapeutics profitable?
- Anika Therapeutics is not currently profitable: it reported a net loss of $11.4M over the trailing twelve months, a -9.8% net margin.
- Where does Anika Therapeutics's income statement data come from?
- Every line is extracted from Anika Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
